Brief: Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas
04/05/2026 12:36
May 4 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 LOTU TRIAL OF FAST TRACK-DESIGNATED QTORIN™ RAPAMYCIN FOR CLINICALLY SIGNIFICANT ANGIOKERATOMAS PALVELLA THERAPEUTICS INC - TOPLINE RESULTS FROM PHASE 2 LOTU TRIAL EXPECTED IN SECOND HALF OF 2027 Source text: ID:nGNXBWXc3 Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs